Thursday, March 14, 2024

6:45 a.m.  Registration, Continental Breakfast and Exhibits

7:30 a.m.  Welcome Announcements
Steven R. Alberts, M.D.

7:40 a.m.  Pre-Test
Steven R. Alberts, M.D.

SESSION I:  Pancreas and Neuroendocrine Cancers

MODERATOR:  Mark J. Truty, M.D., M.S.

7:55 a.m.  Advanced G3 Well Differentiated NET:
Sequencing Treatment Options
Mohamad (Bassam) B. Sonbol, M.D.

8:15 a.m.  Adjuvant, Neoadjuvant and Perioperative Treatment
in the Care of Patients with Resectable Pancreas
Cancer (PDAC): Are We Closer to Picture Perfect?
Zhi Ven Fong, M.D., M.P.H.

8:35 a.m.  NALIRIFOX, FOLFIRINOX or Gemcitabine
Nab-Paclitaxel in Advanced PDAC: Who is a
Candidate?
Michael Jon Pishvaian, M.D., Ph.D.

8:55 a.m.  Emerging Targets in the Treatment of Advanced
PDAC: Are We Getting Closer?
Bassel F. El-Rayes, M.D.

9:15 a.m.  Panel Discussion: A Patient Undergoing Neoadjuvant
Treatment in a Clearly Resectable Patient with PDAC
Moderator: Mark J. Truty, M.D., M.S.
Panelists: Session Presenters, Jason S. Starr, D.O. and
Hani M. Babiker, M.D.

9:45 a.m.  Break and Exhibits
**Thursday, March 14, 2024 (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:05 a.m.</td>
<td>Indication for Transplant in Patients with Early Stage BTC: Who is a Candidate?</td>
<td>Julie K. Heimbach, M.D.</td>
</tr>
<tr>
<td>10:25 a.m.</td>
<td>The Emerging Role of Immunotherapy in the Treatment Landscape of BTC: Is Better Selection Possible?</td>
<td>Lionel A. Kankeu Fonkoua, M.D.</td>
</tr>
<tr>
<td>10:45 a.m.</td>
<td>Advanced Endoscopic Techniques in Diagnosis and Treatment of BTC</td>
<td>Norio Fukami, M.D.</td>
</tr>
<tr>
<td>11:05 a.m.</td>
<td>Her2 as an Emerging Target in BTC</td>
<td>Yoshiaki Nakamura, M.D.</td>
</tr>
<tr>
<td>11:25 a.m.</td>
<td>Panel Discussion: A Patient with Early Stage BTC s/p Resection and Choice of Adjuvant Therapy</td>
<td>Nguyen H. Tran, M.D.</td>
</tr>
<tr>
<td></td>
<td><strong>Panelists:</strong> Session Presenters</td>
<td></td>
</tr>
<tr>
<td>11:55 a.m.</td>
<td>Post-Test</td>
<td>Steven R. Alberts, M.D.</td>
</tr>
<tr>
<td>12:15 p.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Friday, March 15, 2024

6:45 a.m.  Continental Breakfast and Exhibits

7:30 a.m.  Announcements
Tanios S. Bekaii-Saab, M.D.

7:40 a.m.  Pre-Test
Tanios S. Bekaii-Saab, M.D.

SESSION III:  Hepatocellular Cancer (HCC)

MODERATOR:  Nguyen H. Tran, M.D.

7:50 a.m.  Adjuvant Therapy in Patients with High Risk HCC Treated with a Curative Intent
Anthony B. El-Khoueiry, M.D.

8:10 a.m.  Intermediate Stage HCC: At the Intersection of Systemic and Locoregional Approaches
Sadeer J. Alzubaidi, M.D.

8:30 a.m.  Optimizing Sequential Therapies in Advanced HCC
Daniel H. Ahn, D.O.

8:50 a.m.  Systemic Options Pre-Transplant: Is There an Optimal Strategy?
Thomas J. Byrne, M.D.

9:10 a.m.  Panel Discussion: A Patient with Resected Low Risk HCC and Post-op Strategy
Moderator: Sumera I. Ilyas, M.B.B.S.
Panelists: Session Presenters

9:40 a.m.  Break and Exhibits

10:00 a.m.  Special Lecture: Targeting RAS in GI Cancers
Nilofer Azad, M.D.
SESSION IV: Gastroesophageal Cancer (GE)

MODERATOR: Mohamad (Bassam) B. Sonbol, M.D.

10:20 a.m. Minimally Invasive Surgery in GE Cancer: Who is a Candidate? Shanda Blackmon, M.D., M.P.H.

10:40 a.m. Integrating Targeted and/or Immunotherapies in the Treatment Paradigm for Patients with Resectable GE Cancers Harry H. Yoon, M.D.

11:00 a.m. The Expanding Landscape of Therapeutic Options for Patients with HER2+ GE Cancers TBD

11:20 a.m. Beyond HER2 and CPI in the Treatment of Advanced GE Cancers Jason S. Starr, D.O.

11:40 a.m. Panel Discussion: A Patient with Localized Squamous Cell Cancer
Moderator: Mohamad (Bassam) B. Sonbol, M.D.
Panelists: Session Presenters

12:10 p.m. Post-Test Tanios S. Bekaii-Saab, M.D.

12:30 p.m. Adjourn

5:00 p.m. Welcome Reception
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 a.m.</td>
<td>Continental Breakfast and Exhibits</td>
</tr>
<tr>
<td>7:30 a.m.</td>
<td>Announcements</td>
</tr>
<tr>
<td></td>
<td>Steven R. Alberts, M.D., and Tanios S. Bekaii-Saab, M.D.</td>
</tr>
<tr>
<td>7:40 a.m.</td>
<td>Pre-Test</td>
</tr>
<tr>
<td></td>
<td>Steven R. Alberts, M.D., and Tanios S. Bekaii-Saab, M.D.</td>
</tr>
<tr>
<td></td>
<td><strong>SESSION V:</strong> Early-Stage Colorectal Cancer</td>
</tr>
<tr>
<td>MODERATOR:</td>
<td>Steven R. Alberts, M.D</td>
</tr>
<tr>
<td>7:50 a.m.</td>
<td>Radiation Therapy in Early-Stage Rectal Cancer: Who is a Candidate?</td>
</tr>
<tr>
<td></td>
<td>Christopher L. Hallemeier, M.D.</td>
</tr>
<tr>
<td>8:10 a.m.</td>
<td>MSI-H Colon and Rectal Cancer: To Resect or Not to Resect?</td>
</tr>
<tr>
<td></td>
<td>Stacey A. Cohen, M.D.</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>MRD Assessment in Early-Stage CRC: Who and When?</td>
</tr>
<tr>
<td></td>
<td>Jeremy C. Jones, M.D.</td>
</tr>
<tr>
<td>8:50 a.m.</td>
<td>Optimizing Care in Patients with Young Onset Colorectal Cancer</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem, M.D., Ph.D.</td>
</tr>
<tr>
<td>9:10 a.m.</td>
<td>Panel Discussion: A Patient with Localized High Rectal Cancer</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Krishan R. Jethwa, M.D.</td>
</tr>
<tr>
<td></td>
<td><strong>Panelists:</strong> Session Presenters, Jewel J. Samadder, M.D.</td>
</tr>
<tr>
<td>9:40 a.m.</td>
<td>Break and Exhibits</td>
</tr>
</tbody>
</table>
**Saturday, March 16, 2024 (continued)**

**SESSION VI: Advanced Colorectal Cancer**

**MODERATOR:** Christina S. Wu, M.D.

10:00 a.m. **HER2+ mCRC: Optimizing Diagnosis and Treatment Options**
Tanios S. Bekaii-Saab, M.D.

10:20 a.m. **Hyperselection for the Use of EGFR Inhibitors in First Line mCRC**
Takayuki Yoshino, M.D., Ph.D.

10:40 a.m. **Immunoscore and IO in Patients with MSS mCRC: Are We Getting Closer?**
Rondell P. Graham, M.B.B.S.

11:00 a.m. **Expanding Strategies for the Targeting of BRAF V600E MT mCRC**
Mojun Zhu, M.D.

11:20 a.m. **Panel Discussion: A Patient with KRAS G12C MT Colon Cancer**
**Moderator:** Daniel H. Ahn, D.O.
**Panelists:** Session Presenters, Zhaohui Jin, M.D.

11:50 a.m. **Post-Test**
Steven R. Alberts, M.D., and Tanios S. Bekaii-Saab, M.D.

12:10 p.m. **Adjourn**